Edition:
United States

Eleven Biotherapeutics Inc (EBIO.OQ)

EBIO.OQ on NASDAQ Stock Exchange Global Market

0.68USD
15 Dec 2017
Change (% chg)

$0.02 (+3.12%)
Prev Close
$0.66
Open
$0.65
Day's High
$0.72
Day's Low
$0.65
Volume
215,291
Avg. Vol
106,815
52-wk High
$2.53
52-wk Low
$0.63

Chart for

About

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company's product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and... (more)
No analyst recommendations are available for .

Overall

Beta: 3.09
Market Cap(Mil.): $21.53
Shares Outstanding(Mil.): 31.83
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Eleven Biotherapeutics reports Q3 loss per share $0.37

* Eleven Biotherapeutics reports third quarter 2017 financial results

Nov 20 2017

BRIEF-Eleven Biotherapeutics files for non timely 10-Q

* Eleven biotherapeutics inc files for non timely 10-Q - Sec Filing‍​ Source text: (http://bit.ly/2zZDGkA) Further company coverage:

Nov 15 2017

BRIEF-Eleven Biotherapeutics CFO steps down; Richard Fitzgerald named interim CFO

* Eleven Biotherapeutics appoints Richard Fitzgerald as interim chief financial officer

Oct 13 2017

BRIEF-Eleven Biotherapeutics ‍appoints Richard Fitzgerald as interim CFO

* Eleven Biotherapeutics Inc - ‍appointed Richard F. Fitzgerald, age 54, as company's interim Chief Financial Officer, effective October 13, 2017​

Oct 13 2017

BRIEF-Eleven Biotherapeutics files for offering of $12.5 mln common stock

* Eleven biotherapeutics inc- files for offering of $12.5 million common stock Source text for Eikon: (http://bit.ly/2y1EGTF) Further company coverage:

Oct 04 2017

BRIEF-Eleven Biotherapeutics Q2 loss per share $0.30

* Eleven Biotherapeutics reports second quarter 2017 financial results

Aug 14 2017

Earnings vs. Estimates